- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04472013
Systematic Assessment of SARS-CoV-2 Neurotropic Capacity in Modestly and Critically Ill Patients, and Patients Who Died From COVID-19
Study Overview
Status
Conditions
Detailed Description
This study is to analyze the microglia reaction or direct neurotropic effects of CNS COVID-19 in pathogenesis and brain stem dysfunction in critically ill patients. A microglia-focused, brain-specific 50+ marker CODEX panel is used to assess the neuroinflammatory microenvironment in specific brain regions of deceased COVID-19 patients. The peripheral (cerebrospinal fluid and peripheral blood) cytokine response to SARS-CoV-2 is investigated in regard to CNS affection and consecutive blood brain barrier disruption leading to braininherent neuroinflammatory reactions. Primary endpoints of this project are the multidimensional integration of the analysis from the procedures described above and assessment of the correlation between the gained clinical data (MRI, mental/neurological state), the body fluid proteomic and mass-cytometric analysis (CSF and Plasma proteomics, peripheral blood mass cytometry) and the CODEX analysis of defined brain regions on autopsy specimens.
Non-critically ill COVID-19 patients and critically ill COVID-19 patients needing mechanical ventilation at the ICU are included. Autopsy specimens from medulla oblongata, cortex, cerebellum and olfactory bulb are investigated, including only tissue samples, which have been submitted to the Institute of Pathology, University Hospital Basel.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Basel, Switzerland, 4031
- Neurosurgery, University Hospital Basel
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- COVID-19 positive tested
Exclusion Criteria:
- COVID-19 negative tested
- pregnant women
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
MRI imaging data
Time Frame: Project duration for each patient takes 1 hour for the MRI at baseline
|
Comparison of lesions from patients that are neurologically affected to non-affected individuals in terms of CNS involvement to describe encephalitic changes due to COVID-19 infection.
|
Project duration for each patient takes 1 hour for the MRI at baseline
|
Proteomic analysis
Time Frame: 10 minutes for blood draw at baseline
|
Description of proteomic biomarkers (CSF and Plasma) in comparison with control reference sample.
|
10 minutes for blood draw at baseline
|
Peripheral blood leukocyte Cytof Mass Cytometry Analysis for cell population frequency
Time Frame: 10 minutes for blood draw at baseline
|
Mass cytometry will be performed form peripheral blood mononuclear cells to count cell population frequency.
|
10 minutes for blood draw at baseline
|
CODEX (high dimensional microscopy) workflow analysis of defined regions on brain autopsy specimens
Time Frame: at baseline
|
In situ distribution assessment of marker expression (CD147 protein, ACE2 protein, Transmembrane protease serine subtype 2 (TMPRSS2))
|
at baseline
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Gregor Hutter, Prof. Dr. med., Neurosurgery, University Hospital Basel
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2020-01503; ch20Hutter
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19 Disease
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyCompletedPost-COVID-19 Syndrome | Long-COVID-19 SyndromeGermany
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecruitingCOVID-19 Pandemic | COVID-19 Vaccines | COVID-19 Virus DiseaseIndonesia
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
Massachusetts General HospitalRecruitingPost Acute COVID-19 Syndrome | Long COVID | Post Acute Sequelae of COVID-19 | Long COVID-19United States
-
AudibleHealth AI, Inc.Sunrise Research Institute; Analytical Solutions Group, Inc.; Kelley Medical... and other collaboratorsCompletedCoronavirus Disease 2019 | SARS-CoV-2 Infection | COVID-19 Pandemic | COVID-19 Virus Infection | Coronavirus Disease-19 | COVID-19 Virus Disease | 2019 Novel Coronavirus Disease | 2019 Novel Coronavirus Infection | 2019-nCoV DiseaseUnited States
-
Medisch Spectrum TwenteZiekenhuisgroep Twente; University of TwenteActive, not recruiting
-
Karolinska University HospitalKarolinska Institutet; The Swedish Research Council; Region Stockholm; Swedish... and other collaboratorsActive, not recruitingCOVID-19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post COVID Condition | Post-Acute COVID-19 SyndromeSweden
-
Endourage, LLCRecruitingLong COVID | Long Covid19 | Post-Acute COVID-19 | Long Haul COVID | Long-Haul COVID-19 | Post-Acute COVID-19 SyndromeUnited States
-
Indonesia UniversityRecruitingPost-COVID-19 Syndrome | Long COVID | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19Indonesia
Clinical Trials on Data collection from lumbar puncture
-
Michael J. Fox Foundation for Parkinson's ResearchUniversity Health Network, Toronto; University of Rochester; Indiana UniversityCompleted
-
University of NebraskaUnknownIndication for Lumbar PunctureUnited States
-
National Institute of Allergy and Infectious Diseases...Novartis Pharmaceuticals; Autoimmunity Centers of ExcellenceCompletedSecondary Progressive Multiple SclerosisUnited States
-
Dartmouth-Hitchcock Medical CenterTerminated
-
Centre Hospitalier Régional Metz-ThionvilleRecruitingVoluntary Termination of PregnancyFrance
-
Murielle SurquinCompleted
-
Fondazione Don Carlo Gnocchi OnlusFondazione Salvatore Maugeri; Fondazione Poliambulanza Istituto OspedalieroRecruiting
-
BiogenCompletedAngelman Syndrome | Chromosome 15q Duplication (dup15q) SyndromeUnited States
-
IRCCS San RaffaeleTeresa Calimeri; Sara SteffanoniRecruiting
-
Universitair Ziekenhuis BrusselRecruitingAlzheimer Disease | Mild Cognitive ImpairmentBelgium